DE4001060C2 - - Google Patents
Info
- Publication number
- DE4001060C2 DE4001060C2 DE19904001060 DE4001060A DE4001060C2 DE 4001060 C2 DE4001060 C2 DE 4001060C2 DE 19904001060 DE19904001060 DE 19904001060 DE 4001060 A DE4001060 A DE 4001060A DE 4001060 C2 DE4001060 C2 DE 4001060C2
- Authority
- DE
- Germany
- Prior art keywords
- acid
- fatty acid
- treatment
- cis
- trans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 9
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 9
- 229940011871 estrogen Drugs 0.000 claims description 9
- 239000000262 estrogen Substances 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- ADHNUPOJJCKWRT-SENDIRFWSA-N (2z)-octadeca-2,4-dienoic acid Chemical compound CCCCCCCCCCCCCC=C\C=C/C(O)=O ADHNUPOJJCKWRT-SENDIRFWSA-N 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 6
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 102000014654 Aromatase Human genes 0.000 description 8
- 108010078554 Aromatase Proteins 0.000 description 8
- 239000002253 acid Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010046555 Urinary retention Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 229940030486 androgens Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- NPDSHTNEKLQQIJ-UHFFFAOYSA-N 9-hydroxyoctadeca-10,12-dienoic acid Chemical compound CCCCCC=CC=CC(O)CCCCCCCC(O)=O NPDSHTNEKLQQIJ-UHFFFAOYSA-N 0.000 description 2
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 2
- 229960005471 androstenedione Drugs 0.000 description 2
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 2
- 239000003886 aromatase inhibitor Substances 0.000 description 2
- 229940046844 aromatase inhibitors Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 201000004002 Aromatase excess syndrome Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- NPDSHTNEKLQQIJ-KRWDZBQOSA-N Dimorphecolsaeure Natural products CCCCCC=CC=C[C@H](O)CCCCCCCC(O)=O NPDSHTNEKLQQIJ-KRWDZBQOSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 206010027566 Micturition urgency Diseases 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical class CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 238000005899 aromatization reaction Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19904001060 DE4001060A1 (de) | 1990-01-16 | 1990-01-16 | Verwendung einer ungesaettigten fettsaeure oder ihrer derivate in der human- und veterinaermedizin und zur herstellung einer arzneimittelzubereitung |
| AT90121385T ATE90560T1 (de) | 1990-01-16 | 1990-11-08 | Verwendung einer hydroxyoctadecadiensaeure, deren zur ketoform oxidierte saeure sowie deren derivate zur therapie oestrogenabhaengiger krankheiten, sowie pharmazeutische zusammensetzungen, die diese enthalten. |
| ES90121385T ES2057332T3 (es) | 1990-01-16 | 1990-11-08 | Utilizacion de un acido hidroxioctadecadieno sus acidos oxidados en forma ceto asi como sus derivados para terapia de enfermedades dependientes del estrogeno asi como las combinaciones farmaceuticas que lo contengan. |
| DE9090121385T DE59001796D1 (de) | 1990-01-16 | 1990-11-08 | Verwendung einer hydroxyoctadecadiensaeure, deren zur ketoform oxidierte saeure sowie deren derivate zur therapie oestrogenabhaengiger krankheiten, sowie pharmazeutische zusammensetzungen, die diese enthalten. |
| EP90121385A EP0437694B1 (de) | 1990-01-16 | 1990-11-08 | Verwendung einer Hydroxyoctadecadiensäure, deren zur Ketoform oxidierte Säure sowie deren Derivate zur Therapie östrogenabhängiger Krankheiten, sowie pharmazeutische Zusammensetzungen, die diese enthalten |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19904001060 DE4001060A1 (de) | 1990-01-16 | 1990-01-16 | Verwendung einer ungesaettigten fettsaeure oder ihrer derivate in der human- und veterinaermedizin und zur herstellung einer arzneimittelzubereitung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE4001060A1 DE4001060A1 (de) | 1991-07-18 |
| DE4001060C2 true DE4001060C2 (OSRAM) | 1992-02-06 |
Family
ID=6398160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19904001060 Granted DE4001060A1 (de) | 1990-01-16 | 1990-01-16 | Verwendung einer ungesaettigten fettsaeure oder ihrer derivate in der human- und veterinaermedizin und zur herstellung einer arzneimittelzubereitung |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE4001060A1 (OSRAM) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3121152A1 (de) * | 1981-05-22 | 1982-12-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie" |
| AU546872B2 (en) * | 1982-06-16 | 1985-09-26 | Unilever Plc | Skin treatment compositions containing a fatty acid or ester |
| JPH0710774B2 (ja) * | 1986-01-13 | 1995-02-08 | 株式会社ツムラ | アンジオテンシンｉ転換酵素阻害剤 |
-
1990
- 1990-01-16 DE DE19904001060 patent/DE4001060A1/de active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| DE4001060A1 (de) | 1991-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69031033T2 (de) | Verwendung von eicosapentaensäure zur behandlung der kachexie | |
| DE3486235T2 (de) | Fettsäure-Zusammensetzungen. | |
| DE60000133T2 (de) | Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen | |
| DE69518729T2 (de) | Stickstoffoxyd abgebendes präparat zur behandlung von analen erkrankungen | |
| KR100354826B1 (ko) | 스테로이드성 사포닌을 이용한 치매의 예방 치료와스테로이드성 사포닌 화합물 | |
| DE68905863T2 (de) | Zusammensetzungen essentieller fettsaeuren. | |
| DE69315020T2 (de) | Verwendung von Fettsäuren zur Erhöhung der Calciumabsorption im Darm | |
| DE69829097T2 (de) | Cholesterinsenkende Zusammensetzung enthaltend Coenzym Q | |
| DE69612755T2 (de) | Triglyceride und ethylester von phenylalkansäuren und phenylalkensäuren zur behandlung verschiedener erkrankungen | |
| Bernardis | Participation of the dorsomedial hypothalamic nucleus in the “feeding center” and water intake circuitry of the weanling rat | |
| DE2624025A1 (de) | Pharmazeutische zubereitung mit oestrogener wirksamkeit | |
| DE69431965T2 (de) | Wirkstoff gegen fettsucht | |
| DE69807454T2 (de) | Kosmetische oder dermatologische verwendung von 7-hydroxylierten steroiden | |
| Burt et al. | Steroid response to therapy in prostatic cancer | |
| DE29717252U1 (de) | Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen | |
| DE69612540T2 (de) | Verwendung von Hydantoin-Derivaten zur Herstellung eines Medikaments zur Behandlung von Krankheiten in Zusammenhang mit aktivem Sauestoff und freien Radikalen | |
| DE2818586C2 (OSRAM) | ||
| DE2206570C3 (de) | Verwendung von (+)-Catechin | |
| CA2175249A1 (en) | Butyric ester cyto-differentiating agents | |
| EP1063998B1 (de) | Medikament zur prophylaxe und/oder behandlung des mammarkarzinoms enthaltend einen steroidalen aromataseinhibitor | |
| CH637829A5 (de) | Arzneimittel mit wirkung als prostaglandinsynthetaseninhibitor. | |
| DE3902021C2 (OSRAM) | ||
| DE10214005A1 (de) | Blutfettsenker zur oralen Einnahme, bestehend aus einem Gemisch aus den Omega-3-Fettsäuren EPA (Eicosapentaensäure) und DHA (Docosapentaensäure) und Pektin und/oder Guar als wirksame Substanzen, sowie gegebenenfalls zusätzlichen Stoffen wie antioxidative Vitamine, Aminosäuren und Spurenelemente | |
| US3856953A (en) | Method of treating fatty liver | |
| DE3873210T2 (de) | Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: BOOTS PHARMA GMBH, 8884 HOECHSTAEDT, DE |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: KANOLDT ARZNEIMITTEL GMBH, 89420 HOECHSTAEDT, DE |
|
| 8339 | Ceased/non-payment of the annual fee |